116 related articles for article (PubMed ID: 10777146)
1. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.
Phenix BN; Angel JB; Mandy F; Kravcik S; Parato K; Chambers KA; Gallicano K; Hawley-Foss N; Cassol S; Cameron DW; Badley AD
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):559-67. PubMed ID: 10777146
[TBL] [Abstract][Full Text] [Related]
2. Anti-retroviral therapy in HIV-infected patients: in vitro effects of AZT and saquinavir on the response of CD4 and CD8 lymphocytes to interleukin-7.
Beq S; Bugault F; Colle JH; Lambotte O; Delfraissy JF; Thèze J
Eur Cytokine Netw; 2005 Dec; 16(4):293-9. PubMed ID: 16464744
[TBL] [Abstract][Full Text] [Related]
3. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
[TBL] [Abstract][Full Text] [Related]
4. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Rizzardi GP; De Boer RJ; Hoover S; Tambussi G; Chapuis A; Halkic N; Bart PA; Miller V; Staszewski S; Notermans DW; Perrin L; Fox CH; Lange JM; Lazzarin A; Pantaleo G
J Clin Invest; 2000 Mar; 105(6):777-82. PubMed ID: 10727446
[TBL] [Abstract][Full Text] [Related]
5. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection.
Badley AD; Parato K; Cameron DW; Kravcik S; Phenix BN; Ashby D; Kumar A; Lynch DH; Tschopp J; Angel JB
Cell Death Differ; 1999 May; 6(5):420-32. PubMed ID: 10381636
[TBL] [Abstract][Full Text] [Related]
6. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Lucia MB; Rutella S; Leone G; Vella S; Cauda R
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
[TBL] [Abstract][Full Text] [Related]
7. Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure.
Kravcik S; Magill A; Sanghvi B; Ogden R; Cameron WD; Lewis R; Yu G; Badley AD
HIV Clin Trials; 2001; 2(2):160-70. PubMed ID: 11590524
[TBL] [Abstract][Full Text] [Related]
8. Peripheral T-cell apoptosis is not differentially affected by antiretroviral regimens in HIV-infected patients.
Feuth T; van Baarle D; Hoepelman AI; Arends JE
Antivir Ther; 2013; 18(8):1021-5. PubMed ID: 23732862
[TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo.
Sloand EM; Kumar PN; Kim S; Chaudhuri A; Weichold FF; Young NS
Blood; 1999 Aug; 94(3):1021-7. PubMed ID: 10419894
[TBL] [Abstract][Full Text] [Related]
10. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
11. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
12. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.
Ford J; Meaden ER; Hoggard PG; Dalton M; Newton P; Williams I; Khoo SH; Back DJ
J Antimicrob Chemother; 2003 Sep; 52(3):354-8. PubMed ID: 12917239
[TBL] [Abstract][Full Text] [Related]
13. Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection.
Dyrhol-Riise AM; Voltersvik P; Røsok BI; Olofsson J; Asjö B
AIDS Res Hum Retroviruses; 2000 Feb; 16(3):191-201. PubMed ID: 10710207
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy.
Hellinger JA; Cohen CJ; Stein AJ; Gallant JE; Gathe J; Keiser P
HIV Clin Trials; 2000; 1(2):25-8. PubMed ID: 11590495
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
16. Combined antiviral therapy reduces HIV-1 plasma load and improves CD4 counts but does not interfere with ongoing lymphocyte apoptosis.
Moretti S; Alesse E; Marcellini S; Di Marzio L; Zazzeroni F; Parroni R; Famularo G; Boschini A; Cifone MG; De Simone C
Immunopharmacol Immunotoxicol; 1999 Nov; 21(4):645-65. PubMed ID: 10584202
[TBL] [Abstract][Full Text] [Related]
17. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
[TBL] [Abstract][Full Text] [Related]
19. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
Rockstroh JK; Altfeld M; Kupfer B; Kaiser R; Fätkenheuer G; Salzberger B; Schneweis KE; Spengler U
Eur J Med Res; 1999 Jul; 4(7):271-4. PubMed ID: 10425264
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
